Non-Hodgkin lymphoma (differentiating types of NHL): Difference between revisions
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) (Undo revision 1537455 by Preeti Singh (talk)) Tag: Undo |
||
Line 37: | Line 37: | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" color: #FFFFFF;" + |[[Hodgkin's lymphoma|Hodgkin's Lymphoma]] | ! colspan="2" align="center" style="background:#DCDCDC;" color: #FFFFFF;" + |[[Hodgkin's lymphoma|Hodgkin's Lymphoma]]<ref name="pmid8443755">{{cite journal |vauthors=Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S |title=Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis |journal=Cancer |volume=71 |issue=6 |pages=2062–71 |date=March 1993 |pmid=8443755 |doi= |url=}}</ref><ref name="pmid4052959">{{cite journal |vauthors=Gobbi PG, Cavalli C, Gendarini A, Crema A, Ricevuti G, Federico M, Di Prisco U, Ascari E |title=Reevaluation of prognostic significance of symptoms in Hodgkin's disease |journal=Cancer |volume=56 |issue=12 |pages=2874–80 |date=December 1985 |pmid=4052959 |doi= |url=}}</ref><ref name="pmid11238088">{{cite journal |vauthors=Buri C, Körner M, Schärli P, Cefai D, Uguccioni M, Mueller C, Laissue JA, Mazzucchelli L |title=CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease |journal=Blood |volume=97 |issue=6 |pages=1543–8 |date=March 2001 |pmid=11238088 |doi= |url=}}</ref><ref name="pmid9088951">{{cite journal |vauthors=Peh SC, Looi LM, Pallesen G |title=Epstein-Barr virus (EBV) and Hodgkin's disease in a multi-ethnic population in Malaysia |journal=Histopathology |volume=30 |issue=3 |pages=227–33 |date=March 1997 |pmid=9088951 |doi= |url=}}</ref><ref name="pmid9110300">{{cite journal |vauthors=Andriko JA, Aguilera NS, Nandedkar MA, Abbondanzo SL |title=Childhood Hodgkin's disease in the United States: an analysis of histologic subtypes and association with Epstein-Barr virus |journal=Mod. Pathol. |volume=10 |issue=4 |pages=366–71 |date=April 1997 |pmid=9110300 |doi= |url=}}</ref> | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Activation of (NF-kB) | * Activation of (NF-kB) | ||
Line 47: | Line 47: | ||
**[[Interleukin 6|IL-6 gene]] | **[[Interleukin 6|IL-6 gene]] | ||
**IKBA gene | **IKBA gene | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
*[[Fever]] ([[Pel-Ebstein fever]]): persistent temperature >38°C (>100.4°F) | *[[Fever]] ([[Pel-Ebstein fever]]): persistent temperature >38°C (>100.4°F) | ||
Line 78: | Line 77: | ||
|- | |- | ||
| | | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Diffuse large B cell lymphoma]]. | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Diffuse large B cell lymphoma]]<ref name="Colomo2003">{{cite journal |doi=10.1182/blood-2002-04-1286 |pmid=12393466 |title=Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma |journal=Blood |volume=101 |issue=1 |pages=78–84 |year=2002 |last1=Colomo |first1=L. |last2=López-Guillermo |first2=A |last3=Perales |first3=M |last4=Rives |first4=S |last5=Martínez |first5=A |last6=Bosch |first6=F |last7=Colomer |first7=D |last8=Falini |first8=B |last9=Montserrat |first9=E |last10=Campo |first10=E }}</ref><ref name="Hans2004">{{cite journal |doi=10.1182/blood-2003-05-1545 |pmid=14504078 |title=Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray |journal=Blood |volume=103 |issue=1 |pages=275–82 |year=2004 |last1=Hans |first1=C. P. |last2=Weisenburger |first2=D. D. |last3=Greiner |first3=T. C. |last4=Gascoyne |first4=R. D. |last5=Delabie |first5=J |last6=Ott |first6=G |last7=Müller-Hermelink |first7=H. K. |last8=Campo |first8=E |last9=Braziel |first9=R. M. |last10=Jaffe |first10=E. S. |last11=Pan |first11=Z |last12=Farinha |first12=P |last13=Smith |first13=L. M. |last14=Falini |first14=B |last15=Banham |first15=A. H. |last16=Rosenwald |first16=A |last17=Staudt |first17=L. M. |last18=Connors |first18=J. M. |last19=Armitage |first19=J. O. |last20=Chan |first20=W. C. }}</ref><ref name="Muris2006">{{cite journal |doi=10.1002/path.1924 |pmid=16400625 |title=Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma |journal=The Journal of Pathology |volume=208 |issue=5 |pages=714–23 |year=2006 |last1=Muris |first1=JJF |last2=Meijer |first2=Cjlm |last3=Vos |first3=W |last4=Van Krieken |first4=Jhjm |last5=Jiwa |first5=NM |last6=Ossenkoppele |first6=GJ |last7=Oudejans |first7=JJ }}</ref><ref name="pmid27271843">{{cite journal| author=Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M| title=Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. | journal=Adv Anat Pathol | year= 2016 | volume= 23 | issue= 4 | pages= 202-43 | pmid=27271843 | doi=10.1097/PAP.0000000000000117 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27271843 }} </ref><ref>Swerdlow SH, et al (editors). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. 2008. International Agency for Research on Cancer (IARC), Lyon, Franc</ref><ref>Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125</ref>. | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | |
Revision as of 17:02, 18 January 2019
Non-Hodgkin lymphoma Microchapters |
Differentiating Non-Hodgkin's Lymphoma |
---|
Treatment |
Case Studies |
Non-Hodgkin lymphoma (differentiating types of NHL) On the Web |
American Roentgen Ray Society Images of Non-Hodgkin lymphoma (differentiating types of NHL) |
Non-Hodgkin lymphoma (differentiating types of NHL) in the news |
Blogs on Non-Hodgkin lymphoma (differentiating types of NHL) |
Risk calculators and risk factors for Non-Hodgkin lymphoma (differentiating types of NHL) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Overview
Non-Hodgkin lymphoma (differentiating types of NHL)
Differentiating different types of Non-Hodgkin lymphoma. Gold standard for differentiation different types of Non-Hodgkin lymphoma is Biopsy.
Category | Disease | Etiology | Clinical manifestations | Paraclinical findings | Associated findings | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | |||||||||||||||
Symptoms | Signs | CBC | Immunochemistry | Histopathology | |||||||||||
Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Other | WBC | Hb | Plt | |||||||
Hodgkin's Lymphoma[1][2][3][4][5] |
|
|
- | ± | - |
|
|||||||||
Non-Hodgkin's Lymphoma | |||||||||||||||
Diffuse large B cell lymphoma[6][7][8][9][10][11]. |
|
|
- | + | + |
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|||
B Cell Lymphoma | Mantle cell lymphoma |
|
|
Abdominal distention |
|
|
|
↓ | Nl to ↓ |
|
|
||||
B-lymphoblastic leukemia/lymphoma |
|
+ | – | – | – |
|
↓ | ↓ | Nl to ↓ |
| |||||
Follicular lymphoma |
|
Only in 20% of patients: | + | + | ± |
|
↓ | ↓ | Nl to ↓ |
|
|
| |||
Burkitt lymphoma |
|
|
|
|
|||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
|||||||||||||
Splenic marginal zone lymphoma |
|
|
|||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
| ||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
||||||||||||||
Hairy cell leukemia |
|
|
|
||||||||||||
Category | Disease | Etiology | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | Mass | Other | WBC | Hb | Plt | Immunochemistry | Histopathology | Associated findings | |
T cell lymphoma | Precursor T-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||
Adult T cell leukemia/lymphoma |
|
||||||||||||||
Anaplastic large cell lymphoma |
|
||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma |
|
|||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma |
|
||||||||||||||
Enteropathy-type intestinal T-cell lymphoma |
|
||||||||||||||
Extranodal T-cell lymphoma, nasal type |
|
||||||||||||||
Angioimmunoblastic T-cell lymphoma |
|
||||||||||||||
Peripheral T-cell lymphoma, unspecified |
|
- ↑ Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S (March 1993). "Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis". Cancer. 71 (6): 2062–71. PMID 8443755.
- ↑ Gobbi PG, Cavalli C, Gendarini A, Crema A, Ricevuti G, Federico M, Di Prisco U, Ascari E (December 1985). "Reevaluation of prognostic significance of symptoms in Hodgkin's disease". Cancer. 56 (12): 2874–80. PMID 4052959.
- ↑ Buri C, Körner M, Schärli P, Cefai D, Uguccioni M, Mueller C, Laissue JA, Mazzucchelli L (March 2001). "CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease". Blood. 97 (6): 1543–8. PMID 11238088.
- ↑ Peh SC, Looi LM, Pallesen G (March 1997). "Epstein-Barr virus (EBV) and Hodgkin's disease in a multi-ethnic population in Malaysia". Histopathology. 30 (3): 227–33. PMID 9088951.
- ↑ Andriko JA, Aguilera NS, Nandedkar MA, Abbondanzo SL (April 1997). "Childhood Hodgkin's disease in the United States: an analysis of histologic subtypes and association with Epstein-Barr virus". Mod. Pathol. 10 (4): 366–71. PMID 9110300.
- ↑ Colomo, L.; López-Guillermo, A; Perales, M; Rives, S; Martínez, A; Bosch, F; Colomer, D; Falini, B; Montserrat, E; Campo, E (2002). "Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma". Blood. 101 (1): 78–84. doi:10.1182/blood-2002-04-1286. PMID 12393466.
- ↑ Hans, C. P.; Weisenburger, D. D.; Greiner, T. C.; Gascoyne, R. D.; Delabie, J; Ott, G; Müller-Hermelink, H. K.; Campo, E; Braziel, R. M.; Jaffe, E. S.; Pan, Z; Farinha, P; Smith, L. M.; Falini, B; Banham, A. H.; Rosenwald, A; Staudt, L. M.; Connors, J. M.; Armitage, J. O.; Chan, W. C. (2004). "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray". Blood. 103 (1): 275–82. doi:10.1182/blood-2003-05-1545. PMID 14504078.
- ↑ Muris, JJF; Meijer, Cjlm; Vos, W; Van Krieken, Jhjm; Jiwa, NM; Ossenkoppele, GJ; Oudejans, JJ (2006). "Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma". The Journal of Pathology. 208 (5): 714–23. doi:10.1002/path.1924. PMID 16400625.
- ↑ Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M (2016). "Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review". Adv Anat Pathol. 23 (4): 202–43. doi:10.1097/PAP.0000000000000117. PMID 27271843.
- ↑ Swerdlow SH, et al (editors). WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. 2008. International Agency for Research on Cancer (IARC), Lyon, Franc
- ↑ Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125